BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sertanty Inc. Signs Collaboration And Service Agreement With Specs


10/19/2005 5:12:31 PM

SAN JOSE, Calif., Dec. 21 /PRNewswire/ -- Sertanty, Inc., a leading provider of drug discovery cheminformatics products and services, and Specs, a leading supplier of screening compounds and research chemicals, announced today the signing of a collaboration and service agreement to design and produce small molecule libraries targeting several kinase families. Under the agreement, Sertanty will apply its Kinase KnowledgeBase and predictive eScreen(TM) technology to design targeted libraries that Specs will offer to its worldwide customer base of pharmaceutical and biotechnology companies.

Dr. Steven Muskal, CEO of Sertanty, said, "We are very excited to be working with Specs, a premier chemistry partner of the pharmaceutical industry, to provide targeted, drug-like molecules customized to enhance the output of drug discovery efforts. Specs's chemical production and provision know-how is an excellent synergistic match to Sertanty's technology and design capabilities."

"We are delighted to collaborate with Sertanty on the design and production of kinase targeted libraries," said Dr. Johan Tijhuis, CEO of Specs. "Sertanty's excellent technology in designing libraries combined with Specs's compound sourcing and synthesis capabilities will enable us to offer high-quality focused libraries to our customers."

Specs (Delft, The Netherlands) is a leading provider of chemistry and chemistry services for drug discovery. In addition to screening compounds and building blocks, Specs offers cheminformatics and custom synthesis services. Other services include compound reformatting and compound management services. For information contact Specs at info@specs.net or see http://www.specs.net/.

Sertanty, Inc. is headquartered in San Jose, California with sales and support in Boston, Massachusetts. Sertanty provides knowledge-based software, chemistry and Kinase family structure-activity knowledgebases, and collaborative services that accelerate the workflows associated with discovering and evolving novel, medicinally relevant compositions of matter. For information on the company, see http://www.sertanty.com/ .

Sertanty, Inc.

CONTACT: Steve Muskal, CEO of Sertanty, Inc., +1-408-487-4010, orinfo@sertanty.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES